AI-generated analysis. Always verify with the original filing.
Citius Pharmaceuticals, Inc. reported first quarter fiscal 2026 results with $3.9 million revenue from initial LYMPHIR sales and a net loss of $8.2 million applicable to common stockholders. Nasdaq notified the Company on February 9, 2026, of non-compliance with the $1.00 bid price rule, granting 180 days until August 10, 2026, to regain compliance.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject
. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 9, 2026, Nasdaq Stock Market LLC (“Nasdaq”)
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated February 13, 2026. 104 Cover Page Interactive Data File, for
| Metric | Value | Basis |
|---|---|---|
| Revenue | $3.9M | GAAP |
| Gross Profit | $3.2M | GAAP |
| Research and Development Expenses | $1.6M | GAAP |
| General and Administrative Expenses | $5.7M | GAAP |
| Stock-based Compensation Expense | $4.3M | GAAP |
| Net Loss Applicable to Common Stockholders | $-8.2M | GAAP |
| Net Loss Per Share - Basic and Diluted | $-0.38 | GAAP |